SGLT-2 Inhibitors Market Size to Hit USD 31.34 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on SGLT-2 Inhibitors Market

5.1. COVID-19 Landscape: SGLT-2 Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global SGLT-2 Inhibitors Market, By Drug

8.1. SGLT-2 Inhibitors Market Revenue and Volume, by Drug

8.1.1 Jardiance (empagliflozin) – ~50%

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Farxiga (dapagliflozin) – ~25%

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Invokana (canagliflozin) – ~15%

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Inpefa (sotagliflozin) – ~5%

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Qtern (dapagliflozin/saxagliptin) – ~5%

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global SGLT-2 Inhibitors Market, By Indication

9.1. SGLT-2 Inhibitors Market Revenue and Volume, by Indication

9.1.1. Type 2 Diabetes – ~65%

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Cardiovascular Diseases – ~20%

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Chronic Kidney Disease (CKD) – ~10%

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Others – ~5%

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global SGLT-2 Inhibitors Market, By Distribution Channel

10.1. SGLT-2 Inhibitors Market Revenue and Volume, by Distribution Channel

10.1.1. Hospital Pharmacies – ~60%

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Retail Pharmacies – ~25%

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Online Pharmacies – ~15%

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global SGLT-2 Inhibitors Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Drug

11.1.2. Market Revenue and Volume Forecast, by Indication

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Drug

11.1.4.2. Market Revenue and Volume Forecast, by Indication

11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Drug

11.1.5.2. Market Revenue and Volume Forecast, by Indication

11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Drug

11.2.2. Market Revenue and Volume Forecast, by Indication

11.2.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Drug

11.2.4.2. Market Revenue and Volume Forecast, by Indication

11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Drug

11.2.5.2. Market Revenue and Volume Forecast, by Indication

11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Drug

11.2.6.2. Market Revenue and Volume Forecast, by Indication

11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Drug

11.2.7.2. Market Revenue and Volume Forecast, by Indication

11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Drug

11.3.2. Market Revenue and Volume Forecast, by Indication

11.3.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Drug

11.3.4.2. Market Revenue and Volume Forecast, by Indication

11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Drug

11.3.5.2. Market Revenue and Volume Forecast, by Indication

11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Drug

11.3.6.2. Market Revenue and Volume Forecast, by Indication

11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Drug

11.3.7.2. Market Revenue and Volume Forecast, by Indication

11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Drug

11.4.2. Market Revenue and Volume Forecast, by Indication

11.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Drug

11.4.4.2. Market Revenue and Volume Forecast, by Indication

11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Drug

11.4.5.2. Market Revenue and Volume Forecast, by Indication

11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Drug

11.4.6.2. Market Revenue and Volume Forecast, by Indication

11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Drug

11.4.7.2. Market Revenue and Volume Forecast, by Indication

11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Drug

11.5.2. Market Revenue and Volume Forecast, by Indication

11.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Drug

11.5.4.2. Market Revenue and Volume Forecast, by Indication

11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Drug

11.5.5.2. Market Revenue and Volume Forecast, by Indication

11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 12. Company Profiles

12.1. Eli Lilly and Company:

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Boehringer Ingelheim

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Lexicon Pharmaceuticals

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Sanofi

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AstraZeneca:

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Johnson & Johnson

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Merck & Co

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Alkem Laboratories

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Mankind Pharma

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Glenmark Pharmaceuticals

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The SGLT-2 inhibitors market size is expected to increase from USD 18.18 billion in 2025 to USD 31.34 billion by 2034.

The SGLT-2 inhibitors market is expected to grow at a compound annual growth rate (CAGR) of around 6.24% from 2025 to 2034.

The major players in the SGLT-2 inhibitors market include Eli Lilly and Company, Boehringer Ingelheim, Lexicon Pharmaceuticals, Sanofi, AstraZeneca, Johnson & Johnson, Merck & Co, Alkem Laboratories, Mankind Pharma, Glenmark Pharmaceuticals

The driving factors of the SGLT-2 inhibitors market are the driven by rising diabetes prevalence, expanding therapeutic applications, and increasing adoption of combination therapies globally.

North America region will lead the global SGLT-2 inhibitors market during the forecast period 2025 to 2034.